| 0.6057 -0.01 (-1.59%) | 10-13 11:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.07 | 1-year : | 1.33 |
| Resists | First : | 0.92 | Second : | 1.13 |
| Pivot price | 0.73  |
|||
| Supports | First : | 0.56 | Second : | 0.47 |
| MAs | MA(5) : | 0.61 |
MA(20) : | 0.73 |
| MA(100) : | 1.12 |
MA(250) : | 1.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.8 |
D(3) : | 7.5 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 2.44 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BYSI ] has closed above bottom band by 24.0%. Bollinger Bands are 18.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.66 - 0.67 | 0.67 - 0.67 |
| Low: | 0.59 - 0.59 | 0.59 - 0.6 |
| Close: | 0.61 - 0.62 | 0.62 - 0.62 |
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Fri, 09 Oct 2026
Beyondspring Inc (BYSI-Q) Stock Price and News - The Globe and Mail
Wed, 07 Oct 2026
BeyondSpring Divests China Assets, Refocuses on Data Partnerships - The Globe and Mail
Tue, 29 Sep 2026
BYSI Forecast — Price Target — Prediction for 2027 - TradingView
Tue, 29 Sep 2026
About 221 patients are expected to enroll in China, with an investor helping fund the lung cancer trial. - Stock Titan
Fri, 04 Sep 2026
BeyondSpring (NASDAQ: BYSI) Announces 2026 Annual General Meeting with Virtual Access - Kalkine Media
Thu, 03 Sep 2026
BeyondSpring (BYSI) plans Oct. 13 vote on 2026 auditor - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 17.3 (%) |
| Held by Institutions | 14.7 (%) |
| Shares Short | 2,440 (K) |
| Shares Short P.Month | 2,310 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | 11 (M) |
| PE Ratio | -3.37 |
| PEG Ratio | 0 |
| Price to Book value | -0.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|